Boothbay Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boothbay Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,000	Closed	-$1.49M	–	1760
2024 Q3	$1.49M	Buy	+7,000	New	+$1.79M	0.03%	620
2024 Q2	–	Sell	-14,800	Closed	-$3.95M	–	1738
2024 Q1	$3.95M	Buy	+14,800	New	+$3.49M	0.08%	302
2023 Q1	–	Sell	-82,000	Closed	-$23.8M	–	2367
2022 Q4	$23.8M	Buy	82,000 +12,400	+18%	+$1.21M	0.55%	11
2022 Q3	$4.52M	Buy	+69,600	New	+$4.84M	0.11%	219
2020 Q1	–	Sell	-191	Closed	-$1.74M	–	972
2019 Q4	$1.74M	Hold	191	–	–	0.15%	186
2019 Q3	$1.65M	Sell	191 -96	-33%	-$9.01K	0.15%	185
2019 Q2	$3.01M	Buy	+287	New	+$30.7K	0.27%	88
2018 Q4	–	Sell	-57	Closed	-$1.22M	–	788
2018 Q3	$1.22M	Buy	+57	New	+$14.3K	0.12%	163

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's MDGL Position: Q4 2025 in Review

Boothbay Fund Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 1,117 shares — an estimated $512K sold.

Boothbay Fund Management first reported a position in MDGL in Q1 2019 and held it in 12 quarters. The position peaked at $2.18M in Q2 2020. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

Boothbay Fund Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 1,117 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $512K.
Boothbay Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and held it in 12 quarters.
Boothbay Fund Management's Madrigal Pharmaceuticals position peaked at $2.18M in Q2 2020.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.